Glycoprotein News and Research

RSS

Prior symptomatic COVID-19 enhances mRNA vaccine response

A new paper describes the antibody responses in people who have already been infected with SARS-CoV-2 and are vaccinated as compared to the naïve.

14 Sep 2021

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

This study revealed that the CV3-13 antibody can mediate Fc effector functions against S protein-expressing cells.

13 Sep 2021

The strengths and weaknesses of the spike protein in SARS-CoV-2 variants

The S protein has the ability to appropriate various conformations that are dependent on the formation of the receptor-binding domain (RBD) of its protomers.

12 Sep 2021

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Researchers in Australia have developed a coronavirus disease 2019 (COVID-9) vaccine that induced robust and long-lived humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in both young and aging mice.

8 Sep 2021

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Scientists from the National Institutes of Health, USA, have recently demonstrated the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based coronavirus disease 2019 (COVID-19) vaccines in hamsters.

6 Sep 2021

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

The emergence of escape mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is somewhat less likely for the Delta variant in comparison with the original or wild type virus, shows a recent study currently available on the bioRxiv* preprint server while it undergoes peer review.

5 Sep 2021

Do kidney transplant recipients need a third booster dose of mRNA COVID-19 vaccine?

A team of researchers in France have observed that the “standard” 2 dose regimen for mRNA COVID-19 vaccines could provide adequate protection to only a few KTRs. It has also been shown in multiple studies that a considerable population of vaccinated KTRs were easily infected with SARS-CoV-2.

1 Sep 2021

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

A new study published in mBio investigates the impact of the furin cleavage site on viral growth and pathogenesis.

31 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

The influence of COVID-19 on platelet activation and aggregation

In a paper recently uploaded to the bioRxiv* preprint server, humanized ACE2 mice are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and platelets are subsequently isolated from the blood for quantitative proteomic analysis.

26 Aug 2021

SARS-CoV-2 alpha variant increased COVID-19 severity in Scotland's 3rd wave

A team of UK-based scientists has recently revealed that the alpha variant (B.1.1.7) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the third pandemic wave in Scotland and that the variant is associated with more severe coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

25 Aug 2021

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

A new study details the genomic characteristics and descent of a SARS-CoV-2 variant of interest.

23 Aug 2021

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

A new study describes how monoclonal antibodies raised against SARS-CoV-2 are affected by mutations in the antibody binding site.

20 Aug 2021

SARS-CoV-2 lambda variant escapes immune response via spike mutations

A new study explores the mechanism by which the SARS-CoV-2 lambda variant has acquired immune evasion capabilities above that of the wildtype.

20 Aug 2021

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

A striking new study examines how far antibodies elicited by vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or by natural infection, can neutralize the closely related bat coronavirus (CoV) RaTG13.

19 Aug 2021

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

A fascinating and timely new study shows how the Delta variant of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) achieved higher transmissibility and resistance to neutralization.

19 Aug 2021

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

In a recently published article in the journal Virologica Sinica, scientists have described the development and validation of a potent nanobody that targets the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus (SARS-CoV). The nanobody efficiently and specifically blocks the interaction between RBD and angiotensin-converting enzyme 2 (ACE2) and neutralizes the virus.

19 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Glycoprotein News and Research

Prior symptomatic COVID-19 enhances mRNA vaccine response

Efficient non-neutralizing antibody to SARS-CoV-2 spike NTD that operates via Fc receptor-mediated pathway

The strengths and weaknesses of the spike protein in SARS-CoV-2 variants

New vaccinia-based COVID-19 vaccine candidate induces robust, durable immune responses

Vesicular stomatitis virus-based COVID vaccines demonstrate potent antiviral efficacy against SARS-CoV-2 variants

Study finds a restricted number of possible escape mutations for SARS-CoV-2 Delta variant

Do kidney transplant recipients need a third booster dose of mRNA COVID-19 vaccine?

Attenuated virulence and protective immunity in SARS-CoV-2 with a mutation in the S1/S2 cleavage site

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

The influence of COVID-19 on platelet activation and aggregation

SARS-CoV-2 alpha variant increased COVID-19 severity in Scotland's 3rd wave

The emergence and spread of the SARS-CoV-2 Lambda (B.1.621) variant

SARS-CoV-2 mutations alter dynamics of neutralizing antibodies

SARS-CoV-2 lambda variant escapes immune response via spike mutations

SARS-CoV-2 antibodies found to neutralize bat coronavirus (RaTG13) in new study

How does the SARS-CoV-2 Delta variant’s spike drive membrane fusion and immunity evasion?

Scientists identify a potent neutralizing nanobody against SARS-CoV-1

How delta and kappa variants of SARS-CoV-2 evade the immune system

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News